Document is current
Any future updates will be listed below
-
Authors
Giordano, Frank A.
Layer, Julian P. https://orcid.org/0000-0001-7692-7775
Turiello, Roberta https://orcid.org/0009-0000-6356-3917
Friker, Lea L. https://orcid.org/0009-0005-5642-9062
Mirallas, Oriol
Pregler, Barbara E. F.
Potthoff, Anna-Laura
Zeyen, Thomas
Weller, Johannes
Sperk, Elena https://orcid.org/0000-0002-8771-8124
Sahm, Katharina
Oster, Christoph https://orcid.org/0000-0002-0683-0430
Kebir, Sied
Hambsch, Peter
Schäfer, Niklas
Kadzik, Sebastian https://orcid.org/0009-0005-3226-5219
Renovanz, Mirjam
Pietsch, Torsten
Bisdas, Sotirios https://orcid.org/0000-0001-9930-5549
Sepúlveda-Sánchez, Juan Manuel
Gómez-Puerto, Diego
Vieito, Maria
Platten, Michael https://orcid.org/0000-0002-4746-887X
Gkika, Eleni
Grauer, Oliver M. https://orcid.org/0000-0003-4279-4497
Tabatabai, Ghazaleh https://orcid.org/0000-0002-3542-8782
Schneider, Matthias https://orcid.org/0000-0002-6025-7479
Glas, Martin
Seidel, Clemens https://orcid.org/0000-0001-8178-5089
Herrlinger, Ulrich https://orcid.org/0000-0002-4011-9327
Hölzel, Michael https://orcid.org/0000-0003-4048-8824
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1319/TP-B05)
Deutsche Forschungsgemeinschaft (EXC2151–390873048)
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 17 March 2026
First Online: 8 April 2026
Competing interests
: F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG related to this work; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG, OncoMAGNETx Inc. and Varian Medical Systems Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, GUERBET S.A., Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems Inc., and Astra- Zeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG; all unrelated to this work. J.P.L. reports stocks and travel expenses from TME Pharma AG related to this work; travel expenses and honoraria from Carl Zeiss Meditec AG, honoraria and clinical advisory board membership from OncoMAGNETx Inc. and Biotex Inc., stocks and honoraria from Siemens Healthineers AG, and stocks from Bayer AG and BioNTech AG, all unrelated to this work. E.S. reports travel expenses and honoraria from Carl Zeiss Meditec AG, unrelated to this work. C.O. has received travel support from Novocure and honoria by Horizon and Novocure. He has received a Clinician Scientist stipend of the University Medicine Essen Clinician Scientist Academy (UMEA) sponsored by the faculty of medicine and Deutsche Forschungsgemeinschaft (DFG) and a research grant by Servier, all unrelated to this work. N.S. received honoraria from Servier, unrelated to this work. M.P. reports research contributions with Roche Holding AG related to this work. U.H. reports honoraria from Medac, Bayer, Servier and OncoMAGNETx Inc., unrelated to this work. M.H. reports travel expenses, honoraria for webinars, and research support (consumables) from TME Pharma AG related to this work. M.H. also reports honoraria and clinical advisory board membership from OncoMAGNETx Inc., unrelated to this work. The remaining authors declare no competing interests.
